1. Home
  2. OPHC vs PMN Comparison

OPHC vs PMN Comparison

Compare OPHC & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OptimumBank Holdings Inc.

OPHC

OptimumBank Holdings Inc.

N/A

Current Price

$8.69

Market Cap

110.1M

Sector

Finance

ML Signal

N/A

Logo ProMIS Neurosciences Inc. (ON)

PMN

ProMIS Neurosciences Inc. (ON)

N/A

Current Price

$9.38

Market Cap

131.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OPHC
PMN
Founded
2000
2004
Country
United States
Canada
Employees
N/A
N/A
Industry
Major Banks
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
110.1M
131.5M
IPO Year
2012
2022

Fundamental Metrics

Financial Performance
Metric
OPHC
PMN
Price
$8.69
$9.38
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
$10.92
★ $42.71
AVG Volume (30 Days)
★ 79.7K
35.5K
Earning Date
11-09-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ 0.48
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$18.50
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.91
$0.29
52 Week High
$10.68
$27.40

Technical Indicators

Market Signals
Indicator
OPHC
PMN
Relative Strength Index (RSI) 43.05 36.07
Support Level $8.57 $10.78
Resistance Level $9.31 $11.37
Average True Range (ATR) 0.35 0.86
MACD -0.09 -0.25
Stochastic Oscillator 13.36 14.74

Price Performance

Historical Comparison
OPHC
PMN

About OPHC OptimumBank Holdings Inc.

OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides community banking services to individuals and corporate customers. The services provided by the bank include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal accounts, borrowings, repayment of loans, money market deposit accounts, debit cards, automated teller machines, and other bank related services.

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.

Share on Social Networks: